The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Research Report 2025
Synopsis
23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.
The global 23-Valent Pneumococcal Polysaccharide Vaccine market was valued at US$ 1139.5 million in 2023 and is anticipated to reach US$ 1993.7 million by 2030, witnessing a CAGR of 10.3% during the forecast period 2024-2030.
Merck is the largest manufacturers of 23-Valent pneumococcal polysaccharide vaccine in the world, has a share about 78%. Other players include Sinovac, Kangtai Bio, CDIBP, Walvax, etc. United States is dominating the global 23-Valent pneumococcal polysaccharide vaccine market, has a share nearly 78% in terms of production. The largest market is United States, holds a share about 48%, followed by China and Europe, with around 25% and 22% market share respectively.
This report aims to provide a comprehensive presentation of the global market for 23-Valent Pneumococcal Polysaccharide Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding 23-Valent Pneumococcal Polysaccharide Vaccine.
Report Scope
The 23-Valent Pneumococcal Polysaccharide Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global 23-Valent Pneumococcal Polysaccharide Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the 23-Valent Pneumococcal Polysaccharide Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Sinovac
Kangtai Bio
CDIBP
Walvax
Segment by Type
Single Dose Vial
Pre-filled Syringe
Segment by Application
For Children (Over 2 Years Old)
For Adult
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of 23-Valent Pneumococcal Polysaccharide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of 23-Valent Pneumococcal Polysaccharide Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.
The global 23-Valent Pneumococcal Polysaccharide Vaccine market was valued at US$ 1139.5 million in 2023 and is anticipated to reach US$ 1993.7 million by 2030, witnessing a CAGR of 10.3% during the forecast period 2024-2030.
Merck is the largest manufacturers of 23-Valent pneumococcal polysaccharide vaccine in the world, has a share about 78%. Other players include Sinovac, Kangtai Bio, CDIBP, Walvax, etc. United States is dominating the global 23-Valent pneumococcal polysaccharide vaccine market, has a share nearly 78% in terms of production. The largest market is United States, holds a share about 48%, followed by China and Europe, with around 25% and 22% market share respectively.
This report aims to provide a comprehensive presentation of the global market for 23-Valent Pneumococcal Polysaccharide Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding 23-Valent Pneumococcal Polysaccharide Vaccine.
Report Scope
The 23-Valent Pneumococcal Polysaccharide Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global 23-Valent Pneumococcal Polysaccharide Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the 23-Valent Pneumococcal Polysaccharide Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Sinovac
Kangtai Bio
CDIBP
Walvax
Segment by Type
Single Dose Vial
Pre-filled Syringe
Segment by Application
For Children (Over 2 Years Old)
For Adult
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of 23-Valent Pneumococcal Polysaccharide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of 23-Valent Pneumococcal Polysaccharide Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 23-Valent Pneumococcal Polysaccharide Vaccine Market Overview
1.1 Product Overview and Scope of 23-Valent Pneumococcal Polysaccharide Vaccine
1.2 23-Valent Pneumococcal Polysaccharide Vaccine Segment by Type
1.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Single Dose Vial
1.2.3 Pre-filled Syringe
1.3 23-Valent Pneumococcal Polysaccharide Vaccine Segment by Application
1.3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Value by Application: (2024-2030)
1.3.2 For Children (Over 2 Years Old)
1.3.3 For Adult
1.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size Estimates and Forecasts
1.4.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue 2019-2030
1.4.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales 2019-2030
1.4.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 23-Valent Pneumococcal Polysaccharide Vaccine Market Competition by Manufacturers
2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global 23-Valent Pneumococcal Polysaccharide Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of 23-Valent Pneumococcal Polysaccharide Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of 23-Valent Pneumococcal Polysaccharide Vaccine, Product Type & Application
2.7 23-Valent Pneumococcal Polysaccharide Vaccine Market Competitive Situation and Trends
2.7.1 23-Valent Pneumococcal Polysaccharide Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest 23-Valent Pneumococcal Polysaccharide Vaccine Players Market Share by Revenue
2.7.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 23-Valent Pneumococcal Polysaccharide Vaccine Retrospective Market Scenario by Region
3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2019-2030
3.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2019-2024
3.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Region: 2025-2030
3.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region: 2019-2030
3.3.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region: 2019-2024
3.3.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Region: 2025-2030
3.4 North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Facts & Figures by Country
3.4.1 North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2019-2030)
3.4.3 North America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Facts & Figures by Country
3.5.1 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2019-2030)
3.5.3 Europe 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Facts & Figures by Country
3.7.1 Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2019-2030)
3.7.3 Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2019-2030)
4.1.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2019-2024)
4.1.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Type (2025-2030)
4.1.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Type (2019-2030)
4.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2019-2030)
4.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2019-2024)
4.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Type (2025-2030)
4.2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2019-2030)
5.1.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2019-2024)
5.1.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales by Application (2025-2030)
5.1.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Sales Market Share by Application (2019-2030)
5.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2019-2030)
5.2.1 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2019-2024)
5.2.2 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue by Application (2025-2030)
5.2.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global 23-Valent Pneumococcal Polysaccharide Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Sinovac
6.2.1 Sinovac Corporation Information
6.2.2 Sinovac Description and Business Overview
6.2.3 Sinovac 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sinovac 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
6.2.5 Sinovac Recent Developments/Updates
6.3 Kangtai Bio
6.3.1 Kangtai Bio Corporation Information
6.3.2 Kangtai Bio Description and Business Overview
6.3.3 Kangtai Bio 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Kangtai Bio 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
6.3.5 Kangtai Bio Recent Developments/Updates
6.4 CDIBP
6.4.1 CDIBP Corporation Information
6.4.2 CDIBP Description and Business Overview
6.4.3 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 CDIBP 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
6.4.5 CDIBP Recent Developments/Updates
6.5 Walvax
6.5.1 Walvax Corporation Information
6.5.2 Walvax Description and Business Overview
6.5.3 Walvax 23-Valent Pneumococcal Polysaccharide Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Walvax 23-Valent Pneumococcal Polysaccharide Vaccine Product Portfolio
6.5.5 Walvax Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 23-Valent Pneumococcal Polysaccharide Vaccine Industry Chain Analysis
7.2 23-Valent Pneumococcal Polysaccharide Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 23-Valent Pneumococcal Polysaccharide Vaccine Production Mode & Process
7.4 23-Valent Pneumococcal Polysaccharide Vaccine Sales and Marketing
7.4.1 23-Valent Pneumococcal Polysaccharide Vaccine Sales Channels
7.4.2 23-Valent Pneumococcal Polysaccharide Vaccine Distributors
7.5 23-Valent Pneumococcal Polysaccharide Vaccine Customers
8 23-Valent Pneumococcal Polysaccharide Vaccine Market Dynamics
8.1 23-Valent Pneumococcal Polysaccharide Vaccine Industry Trends
8.2 23-Valent Pneumococcal Polysaccharide Vaccine Market Drivers
8.3 23-Valent Pneumococcal Polysaccharide Vaccine Market Challenges
8.4 23-Valent Pneumococcal Polysaccharide Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
